Skip to main content
SpringerLink
Log in

Ranolazine: a guide to its use in chronic stable angina pectoris

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs 2008; 68(17): 2483–503

    Article  PubMed  CAS  Google Scholar 

  2. European Medicines Agency. Ranexa (ranolazine): EU summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2009 Feb 23]

  3. Ranexa® (ranolazine extended-release tablets): US prescribing information. Palo Alto (CA): CV Therapeutics, Inc., 2008 Nov

  4. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27(1): 42–8

    Article  PubMed  CAS  Google Scholar 

  5. Morrow DA, Scirica BM, Chaitman BR, et al. Effect of ranolazine on hemoglobin Alc in the MERLIN-TIMI 36 randomized controlled trial [abstract no. 2453]. Circulation 2007 Oct 16; 116(16 Suppl. II): 539–40

    Google Scholar 

  6. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004 Apr 21; 43(8): 1375–82

    Article  PubMed  CAS  Google Scholar 

  7. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004 Jan 21; 291(3): 309–16

    Article  PubMed  CAS  Google Scholar 

  8. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006 Aug 1; 48(3): 566–75

    Article  PubMed  CAS  Google Scholar 

  9. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007 Apr 25; 297(16): 1775–83

    Article  PubMed  CAS  Google Scholar 

  10. Wilson SR, Morrow DA, Scirica BM, et al. Efficacy and safety of ranolazine in chronic angina: observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI 36 Trial [abstract no. 1031-45]. J Am Coll Cardiol 2008 Mar 11; 51(10 Suppl. A): A225

    Google Scholar 

  11. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007 Mar 13; 49(10): 1027–34

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranolazine: a guide to its use in chronic stable angina pectoris. Drugs Ther. Perspect 25, 1–4 (2009). https://doi.org/10.2165/0042310-200925040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925040-00001

Search

Navigation